Navigation Links
Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
Date:12/8/2008

SAN DIEGO, Dec. 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host a Research and Development Day on Monday, December 15, 2008, beginning at approximately 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time). Speakers, including Jack Lief, President and Chief Executive Officer, Dominic P. Behan, Ph.D., Senior Vice President and Chief Scientific Officer, and William R. Shanahan, M.D., Vice President and Chief Medical Officer, are scheduled to provide an overview of the company, including its clinical development and discovery programs.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at http://www.arenapharm.com. A replay of the presentation will be available for at least 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

     Contacts:  Jack Lief                             Mary Claire Duch
                President and CEO                     WeissComm Partners
                                                      Media Relations
                David Walsey                          212.301.7228
                Director, Corporate Communications

                Arena Pharmaceuticals, Inc.
                858.453.7200, ext. 1682

               http://www.arenapharm.com

'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
2. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
3. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
4. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
5. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
6. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
9. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced ... Siena Center is a skilled nursing facility on the grounds of the St. Catherine’s ... It recently was voted the best nursing home in Mississippi for the second year ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... Endocrinologists at Reproductive Medicine Associates of Connecticut (RMACT) have earned “Top Doctor” ... Murdock and Dr. Shaun Williams have each been chosen by their peers for ...
(Date:1/19/2017)... ... 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to welcome ... Dr. Kim brings an extensive background in cutting-edge dermatology care and research to ... welcome back Dr. Kim to the CDG team” said President and Managing Partner Dr. ...
(Date:1/19/2017)... ... January 19, 2017 , ... "ProParagraph Basics ... simplify the editing process for all media productions," said Christina Austin - CEO ... 30 simplistically styled self-animating paragraphs designed for multi-lined text purposes. Choose from ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
Breaking Medicine Technology: